Biomarker for craving and acamprosate treatment response in patients with alcohol use disorder: insights from multi-omics.

doi:10.1038/s41380-026-03506-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Biomarker for craving and acamprosate treatment response in patients with alcohol use disorder: insights from multi-omics.

Molecular psychiatry - 1 Jul 2026

Ho Ming-Fen, Zhang Cheng, Coombes Brandon J, Biernacka Joanna M, Croarkin Paul E, Oesterle Tyler S, Karpyak Victor M, Li Hu, Weinshilboum Richard M

Abstract excerpt

To date, no objective biochemical markers have been linked to alcohol craving intensity or response to drug treatment for alcohol use disorder (AUD). To address this gap, we aimed to identify potential biomarkers associated with alcohol craving intensity using multi-omics data from the Mayo Clinic acamprosate study-the largest acamprosate trial of its kind and the only one with multi-omics data. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Biomarkers
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrocortisone

Share to Multiomics

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 41741704
DOI: 10.1038/s41380-026-03506-6

Genes

CBLN3
KHNYN
HSD11B1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.